FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.
You may also be interested in...
Chart: Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind
One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.
Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind
One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).